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Background: Staphylococcus aureus nasal carriage is a major
risk factor for nosocomial S. aureus infection. Studies show that
intranasal mupirocin can prevent nosocomial surgical site infec-
tions. No data are available on the efficacy of mupirocin in non-
surgical patients.
Objective: To assess the efficacy of mupirocin prophylaxis in
preventing nosocomial S. aureus infections in nonsurgical patients.
Design: Randomized, double-blind, placebo-controlled trial.
Setting: 3 tertiary care academic hospitals and 1 nonacademic
hospital.
Patients: 1602 culture-proven S. aureus carriers hospitalized in
nonsurgical departments.
Intervention: Therapy with mupirocin 2% nasal ointment (n
793) or placebo ointment (n 809), twice daily for 5 days, started
1 to 3 days after admission.
Measurements: Nosocomial S. aureus infections according to
defined criteria, in-hospital mortality, duration of hospitalization,
and time to nosocomial S. aureus infection. Staphylococcus aureus
isolates were genotyped to assess whether infection was caused
by endogenous strains.
Results: The mupirocin and placebo groups did not statistically
differ in the rates of nosocomial S. aureus infections (mupirocin,
2.6%; placebo, 2.8%; risk difference, 0.2 percentage point [95%
CI, 1.5 to 1.9 percentage points]), mortality (mupirocin, 3.0%;
placebo, 2.8%; risk difference, 0.2 percentage point [CI, 1.9 to
1.5 percentage points]), or duration of hospitalization (median for
both, 8 days). However, time to nosocomial S. aureus infection
was decreased in the mupirocin group from 12 to 25 days (P >
0.2). A total of 77% of S. aureus nosocomial infections were
endogenous.
Limitations: A few infections in both groups may have been
missed because investigators assessed a patient for infection only
if microbiology culture results were positive for S. aureus.
Conclusion: Routine culture for S. aureus nasal carriage at ad-
mission and subsequent mupirocin application does not provide
effective prophylaxis against nosocomial S. aureus infections in
nonsurgical patients.
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Staphylococcus aureus is a frequent cause of nosocomialinfections, including bacteremia and wound infections
(1, 2). Approximately 25% of all nosocomial infections are
caused by S. aureus, affecting both surgical and nonsurgical
patients and leading to increased hospital stay, antibiotic
use, costs, and mortality (3–5). Nasal carriers of S. aureus
have an increased risk for these infections (6–9). Recent
data show that 80% of nosocomial bacteremic S. aureus
strains are endogenous and originate from the nose of S.
aureus carriers (7). Since 20% of the population carries this
pathogen persistently and 60% carries it intermittently, a
substantial number of these nosocomial infections may be
prevented by eliminating S. aureus from the nose (10).
Intranasal application of mupirocin twice daily for 5
days successfully eradicates S. aureus in 83% to 88% of
carriers and reduces S. aureus hand carriage (8, 11–13).
Several studies have shown that patients undergoing sur-
gery or dialysis (peritoneal and hemodialysis) benefit from
S. aureus eradication from the nose because of the reduc-
tion in nosocomial S. aureus infections (10). Mupirocin
prophylaxis has been proven to be effective in preventing
nosocomial S. aureus infections in randomized, placebo-
controlled trials among dialysis and surgical patients and
patients with recurrent skin infections (8, 14–17). Al-
though the efficacy of mupirocin prophylaxis use has been
confirmed only in these patients, mupirocin has many
extralabel indications. The resulting widespread use has
lead to mupirocin resistance (18). Since mupirocin is a
major weapon to control methicillin-resistant S. aureus
outbreaks, it should be used in a prudent and restrictive
manner. Prudent use implies that it be used only for pa-
tients in whom it has proven efficacy.
The efficacy of mupirocin prophylaxis in a general
nonsurgical patient population is not yet known. There-
fore, we decided to study whether mupirocin prophylaxis
in nasal S. aureus carriers hospitalized in nonsurgical wards
decreases the incidence of nosocomial S. aureus infections. We
assessed whether these nosocomial S. aureus infections were
caused by endogenous strains, and we measured the effect of
this intervention on mortality and duration of hospital stay.
METHODS
Design and Patients
This is a multicenter, randomized, double-blind,
placebo-controlled trial. The 4 participating hospitals were
Erasmus University Medical Center (Rotterdam, 1300
beds), University Medical Center St. Radboud (Nijmegen,
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950 beds), VU University Medical Center (Amsterdam,
730 beds), and Amphia Hospital, Langendijk (Breda, 500
beds). The first 3 hospitals are tertiary care hospitals, and
all are teaching hospitals in the Netherlands. The institu-
tional review board of each hospital approved the study.
Between 1 February 1999 and 1 February 2001, adult
patients hospitalized in nonsurgical departments were
screened for nasal S. aureus carriage at the time of admis-
sion. All patients whose screening cultures grew S. aureus
within 72 hours after admission were eligible for the study.
Additional inclusion criteria were age 18 years or older, not
being discharged or expected to be discharged within 1
day, not being transferred to a nonparticipating depart-
ment, and provision of written informed consent. Exclu-
sion criteria were known allergy to mupirocin or glycerin
ester, presence of a nasal tube, recent or current mupirocin
use (mostly patients undergoing hemodialysis or peritoneal
dialysis), and any culture-proven S. aureus infection at the
time of inclusion.
Trial participants were randomly assigned to receive
mupirocin 2% nasal ointment or placebo ointment (both
were obtained from GlaxoSmithKline, Harlow, United
Kingdom) twice daily for 5 days. Mupirocin and placebo
ointments were similar in appearance and odor and were
supplied in identical tubes. Randomization was performed
by a computer-generated allocation list and stratified for
each hospital. The allocation list and study medication
were stored by the departments of medical microbiology
and infectious diseases at the participating centers. Study
personnel and patients were blinded throughout the study.
Study medication was dispensed by trained study person-
nel, who performed the first application according to the
manufacturer’s instructions. Subsequent applications were
done by the patient or nursing personnel according to oral
and written instructions. Patients and nurses were in-
formed about possible adverse events (mainly local irrita-
tion, itching or burning, rhinorrhea, and, rarely, hypersen-
sitivity reactions). They were instructed to report any
adverse event related to the treatment, and medication was
withdrawn if necessary. Patients did not receive follow-up
cultures to check for clearance of S. aureus nasal carriage.
Follow-up and Definitions
At randomization, the following patient data were col-
lected: demographic characteristics, main diagnosis, under-
lying illnesses, immunosuppressive and antibiotic medication,
and presence of indwelling devices or prosthetic material. The
main diagnosis was coded according to the International Clas-
sification of Diseases, Ninth Revision (ICD-9).
Nosocomial S. aureus infections were followed up by
checking the microbiological culture data from any site of
all included patients on a weekly basis until 6 weeks after
discharge. In case of a positive culture result, hospital
records were checked and, if necessary, the treating physi-
cian was interviewed. Nosocomial infections were defined
according to criteria of the Centers for Disease Control
and Prevention (19). A nosocomial infection was caused by
S. aureus when this pathogen was cultured from the site of
infection. Patients with nosocomial S. aureus infection
were considered to have sepsis if 2 or more of the following
conditions were present: temperature greater than 38 °C or
less than 36 °C; heart rate greater than 90 beats/min; re-
spiratory rate greater than 20 breaths/min or PaCO2 level
less than 4.3 kPa; and leukocyte count greater than
12 109 cells/L or less than 4 109 cells/L; or greater
than 10% immature (band) forms, according to standard
criteria (20). Infections that were not clearly nosocomial
were classified by an expert panel of 2 infectious disease
specialists not related to the trial.
Microbiology
Nasal swabs were collected by nursing personnel at
admission. The swabs were streaked onto 5% sheep blood
agar plates (Becton Dickinson, Le Pont de Claix, France),
incubated for 48 hours at 35 °C, and checked each day for
bacterial growth. Suspected colonies were identified as S.
aureus with the Staphaurex Plus agglutination test (Abbott
Murex, Chatillon, France). Patients with positive culture
results were eligible for randomization. The identity of all
positive isolates was later confirmed by an automated sys-
tem (MicroScan Walk-a-Way, Dade-Behring, Inc., West
Sacramento, California). Strains yielding negative results
on confirmation were retested with the AccuProbe hybrid-
ization test (Gen-Probe, Inc., San Diego, California) ac-
cording to the manufacturer’s guidelines. Patients were in-
correctly categorized as nasal carriers of S. aureus if the
agglutination screening test result was positive but both the
subsequent determination with the automated system and
the hybridization test result were negative. Susceptibility to
Context
Topically applied mupirocin can eradicate nasal carriage of
Staphylococcus aureus, but can it prevent S. aureus infec-
tions in nonsurgical, hospitalized patients?
Contribution
In this large double-blind trial, medically ill, hospitalized
patients with positive nasal culture results for S. aureus
were randomly assigned to either mupirocin or placebo
nasal ointment twice daily for 5 days and were followed
until 6 weeks after discharge. Staphylococcus aureus infec-
tion rates were similar among patients given mupirocin
(2.6%) and placebo (2.8%).
Implications
Applying intranasal mupirocin ointment to patients who
carry S. aureus in the nose did not prevent S. aureus infec-
tions in hospitalized, nonsurgical patients.
–The Editors
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mupirocin was tested only in strains causing infections and
was performed by disk diffusion (21).
Infections were treated by the patients’ physician, and
treatment was not influenced by the trial team members.
Cultures were processed according to standard microbio-
logical methods. All S. aureus strains were stored in glycerol
medium at 80 °C. Nasal and clinical S. aureus isolates
from the same patient were genotyped by pulsed-field gel
electrophoresis and were considered to be clonally related if
their genotype patterns did not differ by more than 3
bands according to standard criteria (22).
Sample Size and Statistical Analysis
On the basis of a literature review and prestudy data
from the participating centers, we estimated a priori the
incidence of nosocomial S. aureus infections among S. au-
reus nasal carriers to be 6% (9, 23). Thus, about 800 pa-
tients in each treatment group would demonstrate a statis-
tically significant 50% reduction in nosocomial S. aureus
infections in patients treated with mupirocin (with a power
of 80% and an  level of 0.05).
The primary end point was the incidence of nosoco-
mial S. aureus infections. Secondary outcome measures
were time to nosocomial S. aureus infections, duration of
hospitalization, and in-hospital mortality.
Data were analyzed by using SPSS 10.0 for Windows
(SPSS Inc., Chicago, Illinois). The risks for nosocomial S.
aureus infection and mortality in the 2 treatment groups
were compared by estimating odds ratios, risk differences,
and their 95% CIs per type of infection. Odds ratios with
CIs not containing unity and risk differences with CIs not
containing 0 were considered statistically significant. Dif-
ferences per treatment group in duration of hospitalization
and time to infection were tested for significance by the
Mann–Whitney test. Other categorical variables were com-
pared by Pearson chi-square or Fisher exact test where ap-
propriate. Variables that differed between the 2 treatment
groups by univariate analysis (P  0.1) were included in a
logistic regression model. A P value less than 0.05 was
considered statistically significant.
Data were analyzed on an intention-to-treat and per-
protocol basis. The intention-to-treat analysis contained all
randomly assigned patients fulfilling the inclusion criteria.
The per-protocol analysis excluded the following patients:
those with false-positive diagnoses of S. aureus carriership,
those who did not complete the treatment course, and
those who developed nosocomial S. aureus infection before
the end of their prophylactic course.
Role of the Funding Source
This study was financed by Zon-Mw, The Nether-
lands Organization for Health Research and Development.
This organization had no involvement in the study design,
data collection, data analysis, data interpretation, or writ-
ing of this report.
RESULTS
Enrollment
A total of 17 529 nonsurgical patients were screened
for nasal carriage of S. aureus. Of these patients, 4479
(25.6%) patients were found to have S. aureus nasal car-
riage and 1627 were initially randomly assigned (Figure).
There were 627 patients randomly assigned at Erasmus
Medical Center, 462 patients randomly assigned at the
University Medical Center St. Radboud, 126 patients ran-
domly assigned at the VU University Medical Center, and
412 patients randomly assigned at the Amphia Hospital.
The demographic characteristics of excluded patients did
not differ from those of included patients (data not
shown). In 25 patients hospitalized with an S. aureus in-
fection, the culture results became known after randomiza-
tion and these patients were excluded from analyses (Fig-
ure). Mupirocin was administered to 793 patients and
placebo to 809 patients. Application commenced at a mean
of 1.8 days (range, 1 to 3 days) after admission.
Figure. Study profile.
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The demographic and clinical characteristics of the 2
treatment groups were similar (Table 1). In 24 patients (14
receiving placebo and 10 receiving mupirocin), obstacles to
ointment application occurred. Eleven of these patients
stopped the prophylaxis prematurely. Four of the 24 pa-
tients (2 of which used mupirocin ointment) reported side
effects (itching or burning sensation of the nose). No seri-
ous adverse events were observed or reported.
Intention-to-Treat Analysis
The overall cumulative incidence of nosocomial S. au-
reus infections was 21 of 793 (2.6%) in the mupirocin
group and 23 of 809 (2.8%) in the placebo group (risk
difference, 0.2 percentage point [95% CI, 1.5 to 1.9
percentage points]) (Table 2). In addition, in-hospital
mortality (risk difference, 0.2 percentage point [CI,
1.9 to 1.5 percentage points]) and duration of hospital-
ization did not differ between treatment groups. In each
group, 1 death could be directly related to a nosocomial S.
aureus infection. In patients developing a nosocomial S.
aureus infection, the median time to infection was 25 days
for the mupirocin group and 12 days for the placebo group
(P  0.28). The multiple logistic regression showed that
the following variables were independent risk factors for
nosocomial S. aureus infections: male sex, being immuno-
compromised, and the presence of an indwelling device
(Table 3). Sepsis was diagnosed in 94% of the patients
with nosocomial S. aureus bacteremia and in 83% of pa-
tients with S. aureus pneumonia.
All strains causing nosocomial S. aureus infections
were mupirocin sensitive. Another 1039 S. aureus nasal
strains from this study sample were tested, and none was
found to be mupirocin resistant. Only 1 nasal strain was
methicillin resistant (prevalence, 0.06%). Genotyping of
nasal and subsequent infection strains revealed that 34 of
44 (77.3%) of these strains were clonally related to the
nasal strain (Table 2).
Per-Protocol Analysis
In the per-protocol cohort, the overall cumulative in-
cidence of nosocomial S. aureus infections was 14 of 716
(1.9%) in the mupirocin group and 18 of 742 (2.4%) in
the placebo group (risk difference, 0.5 percentage point
[CI, 1.1 to 2.1 percentage points]). There were no sta-
tistically significant differences in mortality (risk difference,
0.2 percentage point [CI, 2.1 to 1.6 percentage
points]) or duration of hospitalization (Table 2). In pa-
tients developing nosocomial S. aureus infections, the me-
dian time to infection was 32 days in the mupirocin group
and 13 days in the placebo group (P  0.02). The same
variables in the intention-to-treat analysis were used for
logistic regression analysis. In this analysis, an indwelling
device was the only independent risk factor (Table 3).







Mean (SD) age, y 57.6  16.5 57.4  17.3
Men, n (%) 456 (57.5) 453 (56.0)
Hospitalized in intensive care unit, n (%) 34 (4.3) 53 (6.6)
Underlying illness, n (%)
Diabetes 126 (15.9) 137 (16.9)
Autoimmune disorder 46 (5.8) 56 (6.9)
Neoplasms 136 (17.2) 123 (15.2)
Obstructive pulmonary disease 85 (10.7) 99 (12.3)
Skin disease 99 (12.5) 117 (14.5)
HIV infection 10 (1.3) 8 (1.0)
Post-transplantation 28 (3.5) 14 (1.7)
Renal insufficiency 35 (4.4) 28 (3.5)
Liver function disorder 80 (10.1) 68 (8.4)
Medication, n (%)
Chemotherapy 55 (7.0) 65 (8.0)
Corticosteroids 123 (15.6) 126 (15.6)
Immunosuppressive therapy 44 (5.6) 32 (4.0)
Antibiotics 107 (13.5) 107 (13.3)
Foreign bodies or indwelling devices, n (%)
Central venous access 15 (1.9) 14 (1.7)
Implant 98 (12.4) 95 (11.8)
Urine catheter 29 (3.7) 29 (3.6)
Other indwelling device 24 (3.0) 26 (3.2)
Table 2. Study Outcomes and Corresponding Risk Differences













Nosocomial Staphylococcus aureus infections, n (%)
All† 21 (2.6) 23 (2.8) 0.2 (1.5 to 1.9) 14 (1.9) 18 (2.4) 0.5 (1.1 to 2.1)
Bacteremia 7 (0.9)‡ 10 (1.2) 0.4 (0.7 to 1.5) 4 (0.6) 8 (1.1) 0.5 (0.5 to 1.6)
Pneumonia 5 (0.6) 1 (0.1) 0.5 (1.4 to 0.2) 4 (0.6) 1 (0.1) 0.4 (1.3 to 0.3)
Surgical site infection, n (%) 5 (0.6) 8 (1.0) 0.4 (0.6 to 1.4) 4 (0.6) 5 (0.7) 0.1 (0.8 to 1.1)
Skin or soft-tissue infection, n (%) 2 (0.3) 4 (0.5) 0.2 (0.5 to 1.0) 0 4 (0.5) 0.5 (0.1 to 1.4)
Urinary tract infection, n (%) 2 (0.3) 0 0.3 (0.9 to 0.3) 2 (0.3) 0 0.3 (1.0 to 0.3)
In-hospital mortality, n (%) 24 (3.0) 23 (2.8) 0.2 (1.9 to 1.5) 23 (3.2) 22 (3.0) 0.2 (2.1 to 1.6)
Median hospitalization (interquartile range), d§ 8 (5.0 to 14.0) 8 (5.0 to 15.5) 8 (4 to 14) 8 (5 to 16)
* CIs not containing 0 were considered significant. Differences are expressed as percentage points.
† Identical nasal and clinical isolates as determined by pulsed-field gel electrophoresis: overall, 34 of 44 (77.3%); bacteremia, 14 of 17 (82.4%); pneumonia, 6 of 6 (100%);
surgical site infection, 9 of 13 (69.2%); skin or soft-tissue infection, 4 of 6 (66.7%); and urinary tract infection, 1 of 2 (50.0%).
‡ 1 patient had endocarditis.
§ Mann–Whitney test: intention to treat, P  0.2; per protocol, P  0.19.
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DISCUSSION
This study showed that screening for S. aureus nasal
carriage on admission by routine culture and applying
mupirocin in S. aureus carriers to prevent nosocomial S.
aureus infections in nonsurgical patients is not an effica-
cious strategy. None of the risk differences for the different
types of nosocomial infections and mortality indicated suf-
ficient mupirocin effectiveness to merit treatment (risk dif-
ference for overall infection, 0.2 percentage point [CI,
1.5 to 1.9 percentage points]; risk difference for mortal-
ity, 0.2 percentage point [CI, 1.9 to 1.5 percentage
points]; P  0.05). We found that 82.4% of the bactere-
mic strains were clonally related to the nasal strain at ad-
mission, which confirms the results found by von Eiff and
colleagues (7).
Although the rate of S. aureus nasal carriage found in
this study (25.6%) is within the range described in the
literature (19% to 55%), the incidence of nosocomial S.
aureus infections was far lower than that estimated a priori
(10).
The observed low incidence can be explained by the
relatively small proportion of patients in intensive care in
our study sample. Also, the national trend for shorter hos-
pitalizations reduces the period at risk for nosocomial in-
fections and increases the chance of missing nosocomial S.
aureus infections (24). Furthermore, the few risks described
in the literature are mainly based on patients in the inten-
sive care unit, who are at a greater risk for infection (9, 23).
We detected nosocomial infections by checking the
microbiology reports. This may not be optimal, although 1
study found this method to have a sensitivity of approxi-
mately 90% (25). We believe that we detected most of
these infections, since S. aureus infections usually lead to
clinically evident disease. Since the study was blinded,
missed infections would be evenly distributed between the
treatment groups. A nonsurgical patient population in gen-
eral probably has a relatively low risk for nosocomial S.
aureus infections. This is illustrated by the 1.2% incidence
of nosocomial S. aureus bacteremia in a similar patient
sample, which was found by von Eiff and colleagues (7).
We found a similar incidence in our placebo group and
thus conclude that our study did not have exclusion bias.
Two other randomized, controlled trials that studied
the efficacy of mupirocin in a general surgical and an or-
thopedic patient sample have recently been published (8,
26). These studies also showed little to no efficacy of mupi-
rocin prophylaxis. The general surgery study included both
carriers and noncarriers who were randomly assigned to
either mupirocin or placebo. Overall, 2.3% of mupirocin
recipients and 2.4% of placebo recipients had S. aureus
infections at surgical sites. Among the S. aureus nasal car-
riers, mupirocin-treated patients had statistically signifi-
cantly fewer nosocomial S. aureus infections at any site
(4.0%) than placebo-treated patients (7.7%; odds ratio,
0.49 [CI, 0.25 to 0.92]). However, prophylactic mupirocin
did not statistically significantly reduce the rate of S. aureus
infection at surgical sites (8). The orthopedic trial also in-
cluded carriers and noncarriers receiving a surgical inter-
vention (26). In this study, mupirocin did not reduce the
rate of S. aureus infection at surgical sites (mupirocin,
3.8%; placebo, 4.7%) or the duration of hospital stay. In
the mupirocin group, the rate of endogenous S. aureus
infections was 5 times lower than that in the placebo group
(relative risk, 0.19 [CI, 0.02 to 1.62]).
In our study, the time to infection shifted by almost 2
weeks in the subgroup of patients with nosocomial S. au-
reus infection. Patients in the mupirocin group, who had a
prolonged hospital stay, seemed to catch up in infection
probability after this delay. This may be due to recoloni-
zation with S. aureus from extranasal sites several weeks
after mupirocin prophylaxis was stopped. Several studies
show that recolonization with S. aureus occurs in 38% to
43% of patients after 4 to 6 weeks after mupirocin appli-
cation (11, 12, 27). The role of S. aureus carriage at extra-
nasal sites (for example, throat, skin, and perineum) in
recolonization after mupirocin treatment and in develop-
ing infections needs further study. Staphylococcus aureus
present in a lesion (for example, exit site of an indwelling
device) may not be eradicated by solely applying mupirocin
to the nose. Topical mupirocin application to such sites
may be needed to reduce nosocomial S. aureus infections,
such as line-related sepsis in patients with tunneled, cuffed
hemodialysis catheters (28).
To prevent recolonization, repetitive mupirocin appli-
cation to patients with prolonged hospital stay may have
Table 3. Independent Relationship of Possible Risk Factors for
Nosocomial Staphylococcus aureus Infection*
Variable Odds Ratio (95% CI)†
Intention to Treat Per Protocol
Sex
Men 2.25 (1.12–4.53) 1.9 (0.90–4.39)
Women 1
Renal insufficiency
Present 2.71 (0.97–7.57) 2.93 (0.92–9.37)
Absent 1
Solid tumor
Present 1.65 (0.79–3.39) 1.89 (0.82–4.39)
Absent 1
Liver dysfunction
Present 1.76 (0.77–3.99) 1.84 (0.72–4.68)
Absent 1
Immunocompromised
Present 2.15 (1.13–4.09) 1.61 (0.75–3.47)
Absent 1
Indwelling device
Present 3.41 (1.29–8.98) 3.35 (1.04–10.81)
Absent 1
Study medication
Mupirocin 0.92 (0.50–1.70) 0.77 (0.38–1.57)
Placebo 1
* Obtained by multiple logistic regression. Along with mupirocin prophylaxis vs.
placebo, we included variables in the regression model that were significant
(P  0.1) in the univariate analysis and included skin disease as a confounder.
† CIs not containing unity were considered statistically significant.
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resulted in more efficacy of this prophylactic regimen,
which is the case for patients undergoing dialysis (10).
However, this would affect a small proportion of all pa-
tients, since 90% of the patients in this study were already
discharged within 25 days. Also, many nosocomial S. au-
reus infections occur early after admission. These infections
may not be preventable by nasal application of mupirocin
given a few days after admission. Future studies should
consider screening high-risk patients and starting prophy-
laxis before admission or using a rapid molecular-based
screening method and treating carriers the same day.
Although we did not find mupirocin-resistant strains
in our study, large-scale use might induce more mupirocin-
resistant organisms in the sample (18). Therefore, future
intervention trials should preferably focus on patients who
are known S. aureus carriers and are at high risk for S.
aureus infections, including immunocompromised patients
and patients requiring indwelling devices, as shown by the
regression analysis in this study. This analysis also suggests
that S. aureus carriers who have chronic renal insufficiency
without dialysis indication are at increased risk for S. au-
reus infection.
This study does not support the strategy of routine
culture at admission and subsequent mupirocin application
in S. aureus nasal carriers to prevent S. aureus nosocomial
infection in a general nonsurgical population. Because
more than 80% of nosocomial cases of S. aureus bacteremia
are endogenous, strategies that can effectively and safely
eliminate S. aureus carriage from relevant sites may still
play an important role in preventing infections with this
pathogen. We recommend continued effort in elucidating
the mechanisms leading to S. aureus carriage and subse-
quent infection and ongoing development and testing of
prophylactic strategies.
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